Clinical-pathologic study of depressive symptoms and cognitive decline in old age
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 6, 2014
- Accepted in final form May 17, 2014
- First Published July 30, 2014.
Article Versions
- Previous version (July 30, 2014 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Robert S. Wilson, PhD,
- Ana W. Capuano, PhD,
- Patricia A. Boyle, PhD,
- George M. Hoganson, MD,
- Loren P. Hizel, BA,
- Raj C. Shah, MD,
- Sukriti Nag, MD,
- Julie A. Schneider, MD,
- Steven E. Arnold, MD and
- David A. Bennett, MD
- Robert S. Wilson, PhD,
NONE
NONE
NONE
(1) Aging, Neuropsychology, and Cognition, Consulting Editor, 2004-present; (2) Psychology and Aging, Consulting Editor, 2007-present; (3) Neuropsychology, Consulting Editor, 2014-present.
NONE
NONE
NONE
(1) Pain Therapeutics, Inc.
NONE
NONE
NONE
NONE
(1) NIH/NIA R01AG17917, Co-I, 2001-2014; (2) NIH/NIA P30AG10161, Co-I, 1991-2014; (3) NIH/NIA R01AG34374, Co-I, 2008-2014; (4) NIH/NIA R01AG15819, Co-I, 1998-2014.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ana W. Capuano, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH (R01AG022018 [co-investigator], R01AG017917 [co-investigator], R01AG015819 [co-investigator], P30AG010161 [co-investigator], R01AG043379 [co-investigator], R01HL096944 [co-investigator], and R01AG040039 [co-investigator]).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patricia A. Boyle, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH/NIA R01AG034374, PI; (2) NIH/NIA R01AG033678, PI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- George M. Hoganson, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Loren P. Hizel, BA,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH/NIA, R01AG017917 & P30AG10161, research assistant, 2010-2012
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Raj C. Shah, MD,
advisory board service for (1) Merck & Co., Inc. (2) Genentech, Inc.
NONE
NONE
(1) Journal of Alzheimer's Disease, Associate Editor, 2013
NONE
NONE
NONE
(1) Danone Trading B.V. (2) W. Health, L.P.
NONE
NONE
NONE
(1) Danone Research B.V. (2) Eli Lilly & Co., Inc. (3) Genentech, Inc. (4) Merck & Co., Inc. (5) Metabolic Solutions Development Company (6) Navidea Biopharmaceuticals (7) Takeda Development Center Americas, Inc.
(1) NIH, P30 AG101061, Education and Information Transfer Core Leader and Clinical Core Coinvestigator, 2009-present (2) NIH, P20 MD006886, Leader, Education/Research Training Core & Co-investigator, Community Engagement/Outreach Core, 2012-present (3) NIH U01 AG010483, Site Investigator, 2004-present (4) NIH U01 AG029824, Site Principal Investigator, 2009-present (5) NIH, U01 AG046152, Coinvestigator, 2013-present (6) NIH U01, AG024904, Site Coinvestigator, 2004-2013, Site Principal Investigator 2013-present (7) NIH, RC2 AG03653501, Site Investigator, 2009-2012 (8) NIH R01 AG011101, Examining Geriatrician, 2002-2012 (9) NIH R01 NR009543, Coinvestigator, 2007-2013 (10) NIH, P01 AG009466, Coinvestigator, Administrative Core, 2004-2013 (11) Illinois Department of Public Health, Alzheimer�s Disease Assistance Center, Associate Director, 2012-present (12) PCORI, CDRN-1306-04737, Site Principal Investigator, 2014-present (13) Center for Medicare & Medicaid Services, FP050658, Site Principal Investigator, 2012-present (14) DOD, W81XWH-12-2-0012, Site Investigator, 2012-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sukriti Nag, MD,
NONE
NONE
NONE
NONE
NONE
The blood-brain & Other neural barriers, Springer Science + Business Media,Humana Press, 2011 Nag S (Editor)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julie A. Schneider, MD,
1. served on scientific advisory board for GE Healthcare (2010) 2. served on scientific advisory board for Eli Lilly and Company (2011) 3. served on advisory board for Genetech (2013)
NONE
NONE
2005-current Journal Histochemistry and Cytochemistry (Monitoring editor) 2008-current International Journal of Clinical and Experimental Pathology (IJCEP, ISSN 1936-2625) (Editorial Board) 2010 Journal of Alzheimer's Disease (Associate Editor)
NONE
NONE
NONE
Neuropathology consultant, AVID radiopharmaceuticals 2009-12
NONE
NONE
NONE
AVID radiopharmaceutical phase III clinical trial Neuropathologist 2010-2011
1R01AG042210 (Schneider) 07/1/12- 06/30/17 Epidemiologic Study of TDP-43 Pathology in Aging and Dementia Major goal is to determine whether age-related TDP-43 pathology represents a separate pathologic process associated with a dementia syndrome with a distinct cognitive phenotype and specific genetic risk factors that are separate from AD. Role: Principal investigator R01NS078009 (Buchman) 9/15/12-6/30/17 NINDS The Clinical Profile of Parkinson's Disease (PD) Pathology. The overall goal is to characterize the clinical profile of PD pathology in older persons without a diagnosis of PD. Role: co-investigator R01AG043379 (Buchman) 9/30/12-8/31/17 NIA Brain and Spinal Cord Microvascular Pathology in Late-Life Motor Impairment The overall goal is to test the hypothesis that specific microvascular pathologies in the brain and spinal cord contribute to late-life motor impairment. U01AG016976 (Kukull/Montine) 7/1/12-6/30/13 NIA (Pilot) Optimization of Neuropathologic Assessment of Alzheimer�s Disease; The overall goal is to optimize neuropathologic diagnosis of Alzheimer�s disease for uniformity and accurancy across centers Role: Site Principal Investigator P30 AG10161 (Bennett) 9/30/91-6/30/16 Rush Alzheimer's Disease Core Center Major goals to provide core infrastructure support for research regarding aging/dementia/AD. Role: Associate Director, Core Leader: Neuropathology Core R01 AG031553 (Morris) 3/15/08 � 2/28/13 Epidemiologic Study of Brain Vitamin E, Diet, and Age-Related Neurologic Diseases; Major goal is analyze Vitamin E in brain, CSF, serum, and diet and compare to neuropathology and dementia. Role: Co-Principal Investigator R01 AG17917 (Bennett) 9/30/01-6/30/13 Epidemiologic Study of Neural Reserve and Neurobiology of Aging; Major goals are to identify structural bases of reserve and examine mechanisms risk factors lead to age-related functional impairment. Role: Co-Investigator R01 AG15819 (7/1/98 � 6/30/13 Risk Factors, Pathology and Clinical Expressions of AD The major goals of this project are to examine the pathologic mechanisms through which risk factors lead to clinical AD. Role: Co-investigator P01 AG14449 (Mufson) 9/1/97 � 3/31/13 Neurobiology of Mild cognitive impairment in the Elderly; The major goals are to identify neurobiologic substrates of mild cognitive impairment. Role: Co-investigator (Neuropathologist) R01AG033678-01 (Boyle) 9/15/2009 - 6/30/14 Epidemiologic study of impaired decision making in preclinical Alzheimer�s disease. The overall goal of the proposed epidemiologic study is to examine the causes and consequences of impaired decision-making in old age. Role: Neuropathologist R01AG034374 (Boyle) 8/15/2009 -7/31/14 Characterizing the behavior profile of healthy cognitive aging. Goal is to use innovative statistical approaches to characterize the profile of healthy cognitive aging defined as age-related cognitive change not accounted for by the presence of common neuropathologies (i.e., Alzheimer's disease, cerebral infarcts, and the Lewy body diseases) or terminal decline. Role: Neuropathologist. P01 AG09466 (deToledo-Morrell) 4/1/1991-8/31/12 Anatomic, Physiologic, Cognitive Pathology of AD; major goals- to identify neurobiologic, radiologic, physiologic, cognitive markers with AD; Role: Co-Investigator; Neuropathologist, Administrative Core R01 AG36042 (Bennett) 9/15/09-8/31/14 Exploring the Role of the Brain Epigenome: Cognitive Decline and Life Experiences The goal of the study is to examine the relation of DNA methylation to cognitive decline and life experiences. Role: Neuropathologist R01 HL096944 (Levine) 9/1/09 � 6/30/13 Stroke and aPL: Community-Based Clinicopathologic Study The major goal of this project is to investigate the role and mechanisms of antiphospholipid antibodies (aPL) in the development of pathologically-proven ischemic brain infarction. Role: Neuropathologist R01AG040039 (Arvanitakis) 9/30/11-8/31/16 National Institute on Aging Vascular Cognitive and Motor Decline: Impact of aPL The major goal of this project is to investigate the role and mechanisms of antiphospholipid antibodies (aPL) in the development of cognitive and motor decline in aging. R01AG039478 (Arnold) 4/1/11-3/31/16 National Institute on Aging Targeted Proteomics of Resilient Cognition in Aging The major goal of the study is to identify candidate proteins and pathways that best confer cognitive resilience despite the accumulation of neurodegenerative disease pathology. Role: Neuropathologist R01AG036836 (DeJager) 9/15/11-8/31/15 National Institute on Aging Exploring the Role of the Brain Transcriptome in Cognitive Decline The major goal is to investigate the transcriptome of human brain tissue to identify molecular pathways that contribute to cognitive decline. Role: Neuropathologist
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Steven E. Arnold, MD and
Teva
NONE
NONE
Journal of Alzheimer's Disease
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Eli Lilly; Pfizer; Merck; Neuronetrix; Johnson & Johnson; Baxter; Tohyama
NIH
NONE
Marian S. Ware Family Foundation Barra Foundation; BrightFocus Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- David A. Bennett, MD
(1) Vigorous Minds, Scientific Advisory Board (2) Takeda Pharm - Adjudication committee AD4833/TOMM40_301 study
NONE
Nutricia, paid for travel to scientific meeting
(1) Neurology, Editorial Board; (2) Current Alzheimer Research, Editorial Board; (3) Neuroepidemiology, Editorial Board
NONE
NONE
NONE
(1) Nutricia, Inc., (2) Eli Lilly, Inc., (3) Enzymotec Ltd.,
NONE
NONE
NONE
(1) Nutricia Inc., co-PI (2) Zinfandel, PI
NIH: P30AG10161, PI; R01AG15819, PI; R01AG17917, PI; R01AG36042, PI; U01AG32984, Co-I; R01AG22018, Co-I; R01AG33678, Co-I; R01AG36836, Co-I; R01AG41797, Co-I; R01AG42210, Co-I; U01AG46152, MPI; and Illinois Department Public Health
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Rush Alzheimer's Disease Center (R.S.W., A.W.C., P.A.B., G.M.H., L.P.H., R.C.S., S.N., J.A.S., D.A.B.) and Departments of Behavioral Sciences (R.S.W., P.A.B.), Neurological Sciences (R.S.W., A.W.C., J.A.S., D.A.B.), Pathology (S.N., J.A.S.), and Family Medicine (R.C.S.), Rush University Medical Center, Chicago, IL; and Departments of Psychiatry and Neurology (S.E.A.), University of Pennsylvania, Philadelphia.
- Correspondence to Dr. Wilson: rwilson{at}rush.edu
Article usage
Cited By...
Letters: Rapid online correspondence
- Prevention of cognitive decline in old age by antidepressant treatment?
- Hagen Kunte, Neurologist and Psychiatrist, Charit? - Universit?tsmedizin Berlinhagen.kunte@charite.de
- Golo Kronenberg, Berlin, Germany; Rainer Hellweg, Berlin, Germany
Submitted October 16, 2014 - Re:Prevention of cognitive decline in old age by antidepressant treatment?
- Robert S. Wilson, Professor, Rush University Medical Center, Chicago, ILrwilson@rush.edu
Submitted October 16, 2014 - Depressive symptoms and cognitive decline in aging: is sleep a possible modulator?
- Andre C. Boin, Universidade Federal de Sao Pauloandre.c.boin@gmail.com
- Camila Hirotsu, Sao Paulo, Brazil, Monica Levy Andersen, Sao Paulo, Brazil and Sergio Tufik, Sao Paulo, Brazil
Submitted September 08, 2014 - Re:Prevention of cognitive decline in old age by antidepressant treatment?
- Donald R. Royall, Professor of Psychiatry, University of Texas Health Science Center at San Antonioroyall@uthscsa.edu
Submitted August 26, 2014
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hemiplegic Migraine Associated With PRRT2 Variations A Clinical and Genetic Study
Dr. Robert Shapiro and Dr. Amynah Pradhan